There was this reference to T-Cell response:
Admedus Vaccines
Admedus Vaccines initiated and completed the first clinical study for the Herpes Simplex Virus 2 (HSV-2) programme during the financial year. The Study was designed to investigate whether individuals with no prior exposure to HSV-2 could generate some immunity against the virus. The Study had a positive outcome, with the vaccine being shown to be safe as well as being able to stimulate a T-cell response.
However, I'm not sure if this is new information or not? Possibly confirming T-Cell response?
There was this reference to T-Cell response: Admedus Vaccines...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |